(Q38353709)

English

Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

author name string

Victor A Gault

1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Finbarr P M O'Harte

2

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Patrick Harriott

3

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Peter R Flatt

4

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

publication date

1 June 2003

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

52

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

679-687

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Stimulation of insulin secretion by gastric inhibitory polypeptide in man

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Further purification of a polypeptide demonstrating enterogastrone activity

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Nutrient regulation of the enteroinsular axis and insulin secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

The isolation and sequencing of human gastric inhibitory peptide (GIP)

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Glucagonlike peptide 1: a newly discovered gastrointestinal hormone

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Effects of Non-Glycated and Glycated Glucagon-Like Peptide-1(7-36) Amide on Glucose Metabolism in Isolated Mouse Abdominal Muscle

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Gastric inhibitory polypeptide: the neglected incretin revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

A synthetic glucagon-like peptide-1 analog with improved plasma stability

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Determination of glucose by an automatic analyser

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

The insulinotropic action of gastric inhibitory polypeptide in the perfused isolated rat pancreas

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Plasma immunoreactive gastric inhibitory polypeptide in obese hyperglycaemic (ob/ob) mice

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Biological activity of GLP-1-analogues with N-terminal modifications

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0026-0495%2803%2900027-1

7 January 2021

Identifiers

10.1016/S0026-0495(03)00027-1

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38353709&oldid=1755635578"